Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

DTIL
Precision BioSciences, Inc. Common Stock
stock NASDAQ

At Close
Aug 7, 2026 3:59:55 PM EDT
7.51USD+1.486%(+0.11)240,102
6.20Bid   8.95Ask   2.75Spread
Pre-market
Aug 6, 2026 9:27:30 AM EDT
6.95USD-6.961%(-0.52)0
After-hours
Aug 7, 2026 4:00:30 PM EDT
7.49USD-0.266%(-0.02)27,260
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 25, 2022
09:03AM EST  Thomson, Ph.D. as Chief Scientific Officer and Two Additional Senior Appointments   PR Newswire
Jan 5, 2022
11:07AM EST  Stocks That Hit 52-Week Lows On Wednesday   Benzinga
Dec 11, 2021
04:46PM EST  Precision BioSciences Announced Clinical Program Updates for Its Allogeneic CAR T Pipeline at ASH 2021; Said High Response Rates to PBCAR0191 Observed in Heavily Treated Patients Who Relapsed Following Prior Autologous CAR T Therapy   Benzinga
Dec 6, 2021
04:50PM EST  Precision BioSciences To Host Webcast, Conference Call On Saturday, Dec. 11, 2021 To Review Interim Phase 1/2a Data For Its CAR-T Cell Candidate   Benzinga
06:07AM EST  The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More   Benzinga
Dec 3, 2021
04:04PM EST  Precision BioSciences To Present Preclinical Gene Editing Data On Its ARCUS-Based Chronic Hepatitis B Program At The HEP DART 2021 Conference   Benzinga
Nov 30, 2021
04:44PM EST  Precision Biosciences Granted U.S. Patent #11,186,822 'Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)'   Benzinga
Nov 11, 2021
11:55AM EST  Precision BioSciences Earnings Perspective: Return On Capital Employed   Benzinga
Nov 10, 2021
07:33AM EST  Precision BioSciences Q3 EPS $(0.19) Beats $(0.59) Estimate, Sales $24.04M Beat $6.02M Estimate   Benzinga
04:09AM EST  Earnings Scheduled For November 10, 2021   Benzinga
Nov 9, 2021
12:07PM EST  Precision BioSciences Earnings Preview   Benzinga
Nov 4, 2021
09:23AM EDT  Precision BioSciences Announces Two Oral Presentations Highlighting Updated Interim Data From Lead PBCAR0191 CAR T Immunotherapy For Relapsed And Refractory B-cell Malignancies At The 63rd Annual Meeting Of The American Society Of Hematology   Benzinga
Oct 20, 2021
08:16AM EDT  The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review   Benzinga
Oct 11, 2021
05:41AM EDT  TLSA: 1H:21 Financial Update   Benzinga
Sep 27, 2021
07:10AM EDT  Precision BioSciences Appoints Michael Amoroso Chief Executive Officer   Benzinga
Sep 20, 2021
11:51AM EDT  TLSA: Partnership with Precision   Benzinga
Sep 10, 2021
09:36AM EDT  Stifel Maintains Buy on Precision BioSciences, Raises Price Target to $26   Benzinga
07:00AM EDT  Precision BioSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference   Business Wire
Sep 9, 2021
08:17AM EDT  The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization   Benzinga
07:41AM EDT  Precision Expects Three Of Preclinical Programs Will Advance To IND/clinical Trial Application In Next Three Years   RTTNews
07:12AM EDT  Precision BioSciences, IECURE Sign License And Collaboration Deal To Develop ARCUS-Based Gene Editing Therapies   RTTNews
07:04AM EDT  Precision BioSciences And iECURE Announce License And Collaboration Agreement To Develop ARCUS-Based Gene Editing Therapies   Benzinga
07:01AM EDT  Precision BioSciences Outlines Clinical Development Strategy for In Vivo Gene Editing Pipeline   Business Wire
Sep 7, 2021
05:41AM EDT  TLSA: Foralumab Now in CAR T   Benzinga
Sep 2, 2021
08:20AM EDT  The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab   Benzinga
05:50AM EDT  Precision BioSciences, Tiziana Life Sciences Announced Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment   Benzinga
02:25AM EDT  Precision BioSciences, Tiziana Life Sciences To Evaluate Foralumab With Allogeneic CAR T Candidates For Cancer Treatment   RTTNews
02:00AM EDT  Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment   Business Wire
02:00AM EDT  Precision BioSciences and Tiziana Life Sciences Announce Exclusive   GlobeNewswire Inc
Aug 25, 2021
07:00AM EDT  Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021   Business Wire
Aug 12, 2021
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
07:38AM EDT  Precision BioSciences: Q2 Earnings Insights   Benzinga
04:14AM EDT  Earnings Scheduled For August 12, 2021   Benzinga
Aug 9, 2021
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Jul 1, 2021
01:41PM EDT  Precision BioSciences Starts Dosing In Blood Cancer Trial With CAR T Therapy   Benzinga
07:00AM EDT  Precision BioSciences Doses First Patient In Phase 1 Allogeneic CAR T Clinical Trial Of PBCAR19B Immune Evading Stealth Cell For Relapsed/Refractory Non-Hodgkin Lymphoma   Benzinga
Jun 28, 2021
09:17AM EDT  Precision BioSciences Moves Higher After Commencing Dosing In PBCAR269A Combination Arm Of Multiple Myeloma Trial   Benzinga
07:02AM EDT  Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma   Benzinga
Jun 4, 2021
07:08AM EDT  Precision BioSciences Reports Progress On Two Strategies To Optimize Durability Of Allogeneic CAR T Therapy In R/R NHL   RTTNews
07:08AM EDT  Precision Biosciences Highlights Progress On 2 Strategies Designed To Optimize Durability of Allogeneic CAR T Therapy in R/R Non-Hodgkin Lymphoma   Benzinga
07:00AM EDT  Precision BioSciences Reports Progress on Two Strategies Designed to Optimize Durability of Allogeneic CAR T Therapy in R/R Non-Hodgkin Lymphoma   Business Wire
Jun 1, 2021
07:08AM EDT  Precision BioSciences Announces Publication Of Study In Nature Communications Using Engineered ARCUS Nuclease To Target Mutant Mitochondrial DNA In Vivo   Benzinga
May 27, 2021
08:24AM EDT  The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs   Benzinga
07:13AM EDT  Precision BioSciences Appoints Alex Kelly As CFO   RTTNews
07:04AM EDT  Precision BioSciences Appoints Alex Kelly as Chief Financial Officer   Benzinga
May 26, 2021
07:00AM EDT  Precision BioSciences to Participate in the Jefferies Virtual Healthcare Conference   Business Wire
May 20, 2021
11:38AM EDT  Precision BioSciences Files For U.S. Patent Titled 'DYSTROPHIN GENE EXON DELETION USING ENGINEERED NUCLEASES'   Benzinga
08:27AM EDT  The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks   Benzinga
May 19, 2021
05:25PM EDT  Pharma/Biotech Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Jun. 4-8, 2021   Benzinga
May 13, 2021
07:29AM EDT  Recap: Precision BioSciences Q1 Earnings   Benzinga
07:18AM EDT  Precision BioSciences Q1 Net Loss $18.7 Mln Or $0.33/Shr Vs loss Of $26.8 Mln Or $0.52/Shr Last Year   RTTNews
07:09AM EDT  Precision BioSciences Q1 EPS $(0.33) Beats $(0.50) Estimate, Sales $16.30M Beat $7.11M Estimate   Benzinga
07:00AM EDT  Precision BioSciences Reports First Quarter and 2021 Financial Results and Provides Business Update   Business Wire
04:15AM EDT  Earnings Scheduled For May 13, 2021   Benzinga
May 11, 2021
12:38PM EDT  Precision BioSciences Shares Move Higher As ARCUS Platform Shows Promising Gene Editing Approach For Transthyretin Amyloidosis   Benzinga
07:00AM EDT  New Preclinical Data Presented at the 2021 American Society of Genetic & Cell Therapy Annual Meeting Highlights Precision BioSciences' ARCUS In Vivo Genome Editing   Business Wire
May 6, 2021
07:00AM EDT  Precision BioSciences to Report First Quarter 2021 Financial Results on May 13, 2021   Business Wire
May 3, 2021
07:00AM EDT  Precision BioSciences Announces Paper Presentation at the Association for Research in Vision and Ophthalmology 2021 Annual Meeting   Business Wire
Apr 27, 2021
04:35PM EDT  Precision BioSciences Announces Poster Presentation at the Upcoming American Society of Gene & Cell Therapy Annual Meeting   Business Wire
Apr 22, 2021
10:59AM EDT  Precision Biosciences US Patent & Trademark Office Abstract 'OPTIMIZED ENGINEERED NUCLEASES HAVING SPECIFICITY FOR THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE'   Benzinga
Apr 16, 2021
08:01AM EDT  The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs   Benzinga
Apr 15, 2021
04:38PM EDT  Precision BioSciences Appoints Renowned Hematologist Alan List, M.D. as Chief Medical Officer   Benzinga
04:16PM EDT  Precision BioSciences Reacquires Global Rights to its Allogeneic CAR T Programs   Benzinga
Apr 6, 2021
08:58AM EDT  Precision BioSciences Begins Search For Next CEO; Matt Kane To Continue Until Successor Identified   RTTNews
08:45AM EDT  Precision BioSciences Announces CEO Transition Plan; Co. To Initiate Search For New CEO   Benzinga
08:35AM EDT  Precision BioSciences Announces CEO Transition Plan   GlobeNewswire Inc
Mar 29, 2021
07:00AM EDT  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS genome editing platform, today announced it will participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Day on April 1, 2021.   GlobeNewswire Inc
Mar 18, 2021
09:08AM EDT  ROCE Insights For Precision BioSciences   Benzinga
08:16AM EDT  The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq   Benzinga
07:34AM EDT  Recap: Precision BioSciences Q4 Earnings   Benzinga
07:07AM EDT  Earnings Scheduled For March 18, 2021   Benzinga
07:06AM EDT  Precision BioSciences Reports FY20 EPS $(2.09) Up From $(2.21) YoY, Sales $24.3M Up From $22.2M YoY   Benzinga
07:00AM EDT  Established in vivo genome editing research collaboration and exclusive license agreement with Eli Lilly   GlobeNewswire Inc
Mar 12, 2021
07:00AM EST  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company, today announced it will publish fourth quarter and fiscal year 2020 financial results and provide a business update on Thursday, March 18, 2021.   GlobeNewswire Inc
Mar 2, 2021
07:00AM EST  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS genome editing platform, today announced management will participate in the following upcoming virtual investor conferences:   GlobeNewswire Inc
Feb 24, 2021
11:16AM EST  JonesTrading Initiates Coverage On Precision BioSciences with Buy Rating, Announces Price Target of $27   Benzinga
Feb 19, 2021
08:33AM EST  Precision Bio's ARCUS Gene Editing Platform Is Safe, Durable; Long-Term Animal Study Shows   Benzinga
07:25AM EST  The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko   Benzinga
07:06AM EST  Precision Highlights Publication Of 3-Year Pre-clinical Study Results Showing 'Long-Term Durability And Safety' Of ARCUS In Vivo Gene Editing To Cut LDL Cholesterol Levels In Nonhuman Primates In Molecular Therapy Journal   Benzinga
07:00AM EST  Precision Announces 3-Year Pre-clinical Study Results Showing   GlobeNewswire Inc
Feb 4, 2021
07:00AM EST  Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its proprietary ARCUS genome editing platform, today announced it will participate in the Guggenheim Healthcare Talks 2021 Oncology Day on February 11, 2021 at 2:00 PM ET.   GlobeNewswire Inc
Jan 25, 2021
07:01AM EST  Precision BioSciences Receives Notice Of Allowance For U.S. Patent Application Covering PBCAR19B For Non-Hodgkin Lymphoma   Benzinga
07:00AM EST  Precision BioSciences Receives Notice of Allowance for U.S. Patent   GlobeNewswire Inc
Jan 22, 2021
07:22AM EST  The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa   Benzinga
Jan 21, 2021
11:55AM EST  Precision BioSciences shares were trading higher. Not seeing any company-specific news to justify the price action.   Benzinga
08:05AM EST  The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping   Benzinga
Jan 20, 2021
07:32AM EST  The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study   Benzinga
Jan 19, 2021
08:56AM EST  Precision BioSciences Announces FDA Accepts IND For PBCAR19B, A Stealth Cell, CD19 Allogeneic CAR T Candidate For Non-Hodgkin Lymphoma   Benzinga
07:00AM EST  Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a   GlobeNewswire Inc
Jan 7, 2021
07:15AM EST  Precision BioSciences Announces Closing Of In Vivo Gene Editing Collaboration And License Agreement With Eli Lilly Following Clearance Under Hart-Scott-Rodino Antitrust Improvements Act of 1976; Co. To receive $100M Upfront cash Payment   Benzinga
07:15AM EST  Precision BioSciences Announces Closing Of In Vivo Gene Editing Collaboration With Eli Lilly   RTTNews
07:00AM EST  Precision BioSciences Announces Closing of In Vivo Gene Editing   GlobeNewswire Inc
Jan 4, 2021
07:00AM EST  Precision BioSciences to Present at the Annual J.P. Morgan   GlobeNewswire Inc
Dec 14, 2020
12:41AM EST  Precision BioSciences, Inc. (DTIL) said Abid Ansari, CFO, will be leaving the organization. He will continue with Precision through the end of 2020 to ensure a smooth transition. Alex Kelly, Chief Corporate Affairs Officer, will serve as the Interim Chief Financial Officer. Shane Barton, Vice President and Corporate Controller, will serve as interim principal accounting officer.   RTTNews
12:33AM EST  Precision BioSciences Says CFO Abid Ansari To Leave To Pursue A New Career Opportunity   RTTNews
12:00AM EST  Precision BioSciences Announces Executive Leadership Change   GlobeNewswire Inc
Dec 11, 2020
11:00AM EST  Elo Life Systems, a technology driven food and agriculture company headquartered in Durham, N.C., today announced publication of the most comprehensive genome sequence of commercial vanilla species to date. The data, which Elo developed with scientists at the Tropical Research and Extension Center (TREC) at the University of Florida, was published today in Nature Food.   GlobeNewswire Inc
Dec 7, 2020
08:06AM EST  10 Biggest Price Target Changes For Monday   Benzinga
06:59AM EST  JP Morgan Downgrades Precision BioSciences to Neutral, Lowers Price Target to $10   Benzinga
Dec 4, 2020
06:37AM EST  Precision BioSciences Reports Positive Interim Results From PBCAR0191 Phase 1/2a Trial In R/R NHL And R/R B-ALL   RTTNews
06:31AM EST  UPDATE: Precision Says 'PBCAR0191 with Enhanced Lymphodepletion Resulted in Objective Response Rate of 83% (5/6) in NHL and B-ALL'   Benzinga
06:31AM EST  UPDATE: Precision Says 'PBCAR0191 Demonstrated Longest Durability of Response to 11 months in B-ALL'   Benzinga
06:31AM EST  Precision BioSciences Reports Interim Results From Phase 1/2a Trial In Relapsed/Refractory Non-Hodgkin Lymphoma and R/R B-cell Acute Lymphoblastic Leukemia: Acceptable Tolerability and Safety Profile in 27 Patients with No Graft versus Host Disease   Benzinga
06:30AM EST  Acceptable Tolerability and Safety Profile in 27 Patients with No Graft versus Host Disease (GvHD), No Grade 3 Cytokine Release Syndrome (CRS),and NoGrade 3 Neurotoxicity (ICANS)   GlobeNewswire Inc
Nov 24, 2020
04:05PM EST  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS genome editing platform, today announced that its Chief Scientific Officer, Derek Jantz, Ph.D., will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference, November 30 December 3, 2020.   GlobeNewswire Inc
Nov 20, 2020
09:56AM EST  Precision BioSciences, Inc. (DTIL) shares are gaining more than 10 percent on Friday morning, as the company announced a research collaboration and exclusive license agreement with Eli Lilly and Co. (LLY).   RTTNews
08:06AM EST  The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger   Benzinga
07:26AM EST  Eli Lilly and Co. (LLY) and Precision BioSciences Inc. (DTIL) announced a genome editing research collaboration and license agreement.   RTTNews
07:02AM EST  Eli Lilly, Precision BioSciences Announce Research Collaboration And Exclusive License Agreement   RTTNews
07:02AM EST  Eli Lilly, Precision BioSciences Report Research Collaboration, Exclusive License Deal To Utilize Precision's Proprietary ARCUS Genome Editing Platform For R&D Of Potential In Vivo Therapies For Genetic Disorders   Benzinga
07:00AM EST  Lilly and Precision BioSciences Announce Genome Editing Research Collaboration   PR Newswire
Nov 10, 2020
08:40AM EST  The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies   Benzinga
07:00AM EST  Expanded allogeneic CAR T development collaboration with Servier to include four new programs targeting hematological and solid tumors   GlobeNewswire Inc
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 3, 2020
07:00AM EST  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS genome editing platform, today announced that it will publish financial results for the third quarter of 2020 and provide a business update on Tuesday, November 10, 2020.   GlobeNewswire Inc
Oct 15, 2020
07:06AM EDT  Precision BioSciences Announces US Patent Trial And Appeal Board Upholds Allogeneic CAR T Patents   Benzinga
07:00AM EDT  Precision BioSciences Announces U.S. Patent Trial and Appeal Board   GlobeNewswire Inc
Oct 14, 2020
07:00AM EDT  Precision BioSciences Appoints Alex Kelly as Chief Corporate   GlobeNewswire Inc
Sep 28, 2020
07:00AM EDT  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS genome editing platform, today announced its participation in the following upcoming virtual investor conferences:   GlobeNewswire Inc
Sep 21, 2020
07:15AM EDT  Precision BioSciences, SpringWorks Therapeutics Collaborate To Evaluate PBCAR269A In Combination With Nirogacestat   RTTNews
07:06AM EDT  Precision BioSciences And SpringWorks Therapeutics Announce Clinical Collaboration To Evaluate PBCAR269A In Combination With Nirogacestat In Patients With Relapsed Or Refractory Multiple Myeloma   Benzinga
07:00AM EDT  Precision BioSciences and SpringWorks Therapeutics Announce   GlobeNewswire Inc
Sep 17, 2020
07:08AM EDT  Precision BioSciences And Servier Expand CAR T Oncology Development Collaboration, Announce Four New Programs Targeting Hematological And Solid Tumors   Benzinga
07:00AM EDT  Precision BioSciences and Servier Expand CAR T Oncology   GlobeNewswire Inc
Sep 9, 2020
10:03AM EDT  Why Precision BioSciences' Stock Is Trading Higher Today   Benzinga
07:27AM EDT  Precision BioSciences Receives Fast Track Designation From FDA For PBCAR269A Investigational Allogeneic CAR T Therapy For Relapsed/Refractory Multiple Myeloma   Benzinga
07:00AM EDT  Precision BioSciences Receives Fast Track Designation from U.S.   GlobeNewswire Inc
Sep 2, 2020
07:00AM EDT  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS genome editing platform, today announced its participation in the following upcoming investor conferences:   GlobeNewswire Inc
Aug 19, 2020
09:42AM EDT  Precision BioSciences shares are trading higher after the company announced it has received fast track designation for the FDA for its PBCAR0191 investigational Allogeneic CAR T Cell Therapy.   Benzinga
07:14AM EDT  Precision BioSciences Receives Fast Track Disease Designation From FDA For PBCAR0191 Investigational Allogeneic CAR T Cell Therapy   Benzinga
07:14AM EDT  Precision BioSciences: FDA Grants Fast Track Designation For PBCAR0191 Investigational Allogeneic CAR T Cell Therapy   RTTNews
07:00AM EDT  Precision BioSciences Receives Fast Track Disease Designation from   GlobeNewswire Inc
Aug 13, 2020
07:31AM EDT  Precision BioSciences: Q2 Earnings Insights   Benzinga
07:05AM EDT  Precision BioSciences, Inc. - Common Stock Q2 EPS $(0.63) Misses $(0.59) Estimate, Sales $1.10M Miss $4.39M Estimate   Benzinga
07:00AM EDT  Dosed First Patient in Phase 1/2a Clinical Trial of PBCAR269A, a BCMA-Targeted Allogeneic CAR T Candidate for Multiple Myeloma   GlobeNewswire Inc
04:03AM EDT  Earnings Scheduled For August 13, 2020   Benzinga
Aug 4, 2020
07:36AM EDT  Precision BioSciences' Subsidiary, Elo Life Systems, Reports Strategic Partnership With Dole Food Co. To Develop Multiple Banana Varieties, No Terms Disclosed   Benzinga
07:00AM EDT  Elo Life Systems, a food and agriculture company with a mission to improve human health and wellness, today announced a strategic partnership with the Dole Food Company, one of the worlds largest producers of high-quality fresh fruit and vegetables, aiming to develop multiple banana varieties, including Cavendish, with resistance to the devastating fungal disease, Fusarium wilt.   GlobeNewswire Inc
Aug 3, 2020
07:00AM EDT  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS genome editing platform today announced it will report financial results for the second quarter of 2020 on August 13, 2020.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC